CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
66.71
0.79%
Market Trading Hours* (UTC) Opens on Monday at 08:10

Mon - Thu: 08:10 - 00:00

Fri: 08:10 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.23
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Gilead Sciences Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 66.19
Open* 66.19
1-Year Change* -20.48%
Day's Range* 65.73 - 66.72
52 wk Range 72.87-87.82
Average Volume (10 days) 6.68M
Average Volume (3 months) 131.04M
Market Cap 107.66B
P/E Ratio 18.53
Shares Outstanding 1.25B
Revenue 27.39B
EPS 4.66
Dividend (Yield %) 3.47222
Beta 0.21
Next Earnings Date Feb 6, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 66.71 0.98 1.49% 65.73 66.77 65.73
Apr 18, 2024 66.18 -0.62 -0.93% 66.80 67.16 65.85
Apr 17, 2024 66.84 -0.43 -0.64% 67.27 67.48 66.84
Apr 16, 2024 67.27 -0.21 -0.31% 67.48 67.78 67.13
Apr 15, 2024 67.62 -0.17 -0.25% 67.79 68.51 67.62
Apr 12, 2024 67.84 -0.31 -0.45% 68.15 68.64 67.57
Apr 11, 2024 68.51 0.48 0.71% 68.03 68.97 67.95
Apr 10, 2024 68.07 -1.40 -2.02% 69.47 69.88 68.00
Apr 9, 2024 69.86 0.99 1.44% 68.87 69.91 68.45
Apr 8, 2024 69.10 0.15 0.22% 68.95 69.55 68.65
Apr 5, 2024 69.47 0.02 0.03% 69.45 69.96 68.49
Apr 4, 2024 69.54 -1.31 -1.85% 70.85 71.34 69.34
Apr 3, 2024 70.85 -1.02 -1.42% 71.87 72.13 70.65
Apr 2, 2024 71.97 -0.93 -1.28% 72.90 72.92 71.85
Apr 1, 2024 72.45 -0.68 -0.93% 73.13 73.46 72.33
Mar 28, 2024 72.97 0.34 0.47% 72.63 73.82 72.55
Mar 27, 2024 72.88 0.56 0.77% 72.32 73.00 72.05
Mar 26, 2024 72.45 0.02 0.03% 72.43 72.62 72.06
Mar 25, 2024 72.69 0.26 0.36% 72.43 72.78 72.16
Mar 22, 2024 72.63 -0.40 -0.55% 73.03 73.33 72.50

Gilead Sciences Inc Events

Time (UTC) Country Event
Thursday, April 25, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Gilead Sciences Inc Earnings Release
Q1 2024 Gilead Sciences Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

20:30

Country

US

Event

Q1 2024 Gilead Sciences Inc Earnings Call
Q1 2024 Gilead Sciences Inc Earnings Call

Forecast

-

Previous

-
Thursday, May 2, 2024

Time (UTC)

17:00

Country

US

Event

Gilead Sciences Inc Annual Shareholders Meeting
Gilead Sciences Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, May 8, 2024

Time (UTC)

17:00

Country

US

Event

Gilead Sciences Inc Annual Shareholders Meeting
Gilead Sciences Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 1, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Gilead Sciences Inc Earnings Release
Q2 2024 Gilead Sciences Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 27281 27305 24689 22449 22127
Revenue 27281 27305 24689 22449 22127
Cost of Revenue, Total 5657 6601 4572 4675 4853
Gross Profit 21624 20704 20117 17774 17274
Total Operating Expense 19951 17387 20618 18162 13927
Selling/General/Admin. Expenses, Total 5673 5246 5151 4381 4056
Research & Development 5921 5540 10895 8934 4846
Unusual Expense (Income) 2700 172 172
Operating Income 7330 9918 4071 4287 8200
Interest Income (Expense), Net Non-Operating -1592 -1611 -2684 227 -964
Other, Net 76 -29 282 646 563
Net Income Before Taxes 5814 8278 1669 5160 7799
Net Income After Taxes 4566 6201 89 5364 5464
Minority Interest 26 24 34 22 -5
Net Income Before Extra. Items 4592 6225 123 5386 5459
Net Income 4592 6225 123 5386 5455
Income Available to Common Excl. Extra. Items 4592 6225 123 5386 5459
Income Available to Common Incl. Extra. Items 4592 6225 123 5386 5455
Dilution Adjustment
Diluted Net Income 4592 6225 123 5386 5455
Diluted Weighted Average Shares 1262 1262 1263 1277 1308
Diluted EPS Excluding Extraordinary Items 3.63867 4.93265 0.09739 4.2177 4.17355
Dividends per Share - Common Stock Primary Issue 2.92 2.84 2.72 2.52 2.28
Diluted Normalized EPS 5.31889 4.93265 0.09739 4.30525 4.26568
Total Extraordinary Items -4
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 6599 6352 7389 7042 6260
Revenue 6599 6352 7389 7042 6260
Cost of Revenue, Total 1442 1401 1396 1395 1442
Gross Profit 5157 4951 5993 5647 4818
Total Operating Expense 4934 4647 5122 4205 4231
Selling/General/Admin. Expenses, Total 1849 1319 2020 1213 1357
Research & Development 1643 1928 1706 1597 1432
Unusual Expense (Income) 0 0 0 0
Operating Income 1665 1705 2267 2837 2029
Interest Income (Expense), Net Non-Operating -161 -486 -287 -426 -545
Other, Net 84 81 51 21 19
Net Income Before Taxes 1588 1300 2031 2432 1503
Net Income After Taxes 1039 984 1633 1786 1135
Minority Interest 6 26 7 3 9
Net Income Before Extra. Items 1045 1010 1640 1789 1144
Net Income 1045 1010 1640 1789 1144
Income Available to Common Excl. Extra. Items 1045 1010 1640 1789 1144
Income Available to Common Incl. Extra. Items 1045 1010 1640 1789 1144
Diluted Net Income 1045 1010 1640 1789 1144
Diluted Weighted Average Shares 1258 1261 1265 1261 1260
Diluted EPS Excluding Extraordinary Items 0.83068 0.80095 1.29644 1.41872 0.90794
Dividends per Share - Common Stock Primary Issue 0.75 0.75 0.73 0.73 0.73
Diluted Normalized EPS 0.83068 0.80095 1.29644 1.41872 0.90794
Other Operating Expenses, Total -1
Total Adjustments to Net Income 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 14443 14772 15996 30296 35836
Cash and Short Term Investments 6385 6520 7408 24352 30089
Cash & Equivalents 5412 5338 5997 11631 17940
Short Term Investments 973 1182 1411 12721 12149
Total Receivables, Net 4777 4493 4892 3582 3327
Accounts Receivable - Trade, Net 4777 4493 4892 3582 3327
Total Inventory 1507 1618 1683 922 814
Prepaid Expenses 1774 2141 2013 1403 1533
Total Assets 63171 67952 68407 61627 63675
Property/Plant/Equipment, Total - Net 5475 5663 5613 5170 4006
Goodwill, Net 8314 8332 8108 4117 4117
Intangibles, Net 28894 33455 33126 13786 15738
Long Term Investments 1245 1309 502 1488 1423
Other Long Term Assets, Total 4800 4421 5062 6770 2555
Total Current Liabilities 11237 11610 11397 9759 10605
Accounts Payable 905 705 844 713 790
Accrued Expenses 7100 7600 7198 6254 6876
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2273 1516 2757 2499 2748
Other Current Liabilities, Total 959 1789 598 293 191
Total Liabilities 41931 46883 50205 39102 42288
Total Long Term Debt 22957 25179 28645 22094 24574
Long Term Debt 22957 25179 28645 22094 24574
Minority Interest -31 -5 19 125 147
Other Liabilities, Total 5095 5743 10144 7124 6962
Total Equity 21240 21069 18202 22525 21387
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 1 1 1 1 1
Additional Paid-In Capital 5550 4661 3880 3051 2282
Retained Earnings (Accumulated Deficit) 15687 16324 14381 19388 19024
Unrealized Gain (Loss) -33 -4 2 1 -52
Other Equity, Total 35 87 -62 84 132
Total Liabilities & Shareholders’ Equity 63171 67952 68407 61627 63675
Total Common Shares Outstanding 1247 1254 1254 1266 1282
Other Current Assets, Total 37 73
Property/Plant/Equipment, Total - Gross 7661 7556 7281 6592 5197
Accumulated Depreciation, Total -2186 -1893 -1668 -1422 -1191
Deferred Income Tax 2673 4356
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 15980 14287 13456 14443 13554
Cash and Short Term Investments 6864 6667 5872 6385 5660
Cash & Equivalents 5705 5704 4936 5412 4699
Short Term Investments 1159 963 936 973 961
Total Receivables, Net 4790 4229 4162 4777 4354
Accounts Receivable - Trade, Net 4790 4229 4162 4777 4354
Total Inventory 1663 1633 1576 1507 1463
Prepaid Expenses 2662 1757 1846 1774 2077
Total Assets 62373 62337 61876 63171 62557
Property/Plant/Equipment, Total - Net 5572 5540 5479 5475 5349
Goodwill, Net 8314 8314 8314 8314 8314
Intangibles, Net 27152 27750 28348 28894 29440
Long Term Investments 1400 2380 2309 1245 1282
Other Long Term Assets, Total 3955 4066 3970 4800 4618
Total Current Liabilities 11945 13964 10528 11237 10423
Accounts Payable 586 622 627 905 614
Accrued Expenses 4675 4258 4184 7100 6637
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1793 4037 2283 2273 2270
Other Current Liabilities, Total 4891 5047 3434 959 902
Total Liabilities 40059 41179 40879 41931 41476
Total Long Term Debt 23189 21209 22956 22957 22953
Long Term Debt 23189 21209 22956 22957 22953
Deferred Income Tax 1984 2106 2401 2673 3036
Minority Interest -72 -64 -58 -31 -24
Other Liabilities, Total 3013 3964 5052 5095 5088
Total Equity 22314 21158 20997 21240 21081
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 1 1 1 1 1
Additional Paid-In Capital 6279 6008 5793 5550 5226
Retained Earnings (Accumulated Deficit) 16002 15138 15223 15687 15756
Unrealized Gain (Loss) -22 -26 -24 -33 -41
Other Equity, Total 54 37 4 35 139
Total Liabilities & Shareholders’ Equity 62373 62337 61876 63171 62557
Total Common Shares Outstanding 1247 1247 1248 1247 1254
Other Current Assets, Total 1 1
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 4566 6201 89 5364 5460
Cash From Operating Activities 9072 11384 8168 9144 8400
Cash From Operating Activities 323 329 288 255 226
Amortization 1780 1721 1192 1149 1203
Deferred Taxes -1552 -116 -214 -2098 289
Non-Cash Items 5718 2760 8451 5272 2161
Cash Taxes Paid 3136 2509 2639 1793 3198
Cash Interest Paid 907 979 951 982 1070
Changes in Working Capital -1763 489 -1638 -798 -939
Cash From Investing Activities -2466 -3131 -14615 -7817 14355
Capital Expenditures -728 -579 -650 -825 -924
Other Investing Cash Flow Items, Total -1738 -2552 -13965 -6992 15279
Cash From Financing Activities -6469 -8877 770 -7634 -12318
Financing Cash Flow Items -173 -145 -138 -122 -486
Total Cash Dividends Paid -3709 -3605 -3449 -3222 -2971
Issuance (Retirement) of Stock, Net -1087 -377 -1327 -1540 -2611
Issuance (Retirement) of Debt, Net -1500 -4750 5684 -2750 -6250
Foreign Exchange Effects -63 -35 43 -2 -85
Net Change in Cash 74 -659 -5634 -6309 10352
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 985 4566 2933 1147 12
Cash From Operating Activities 1743 9072 6505 3642 1840
Cash From Operating Activities 94 323 240 160 80
Amortization 546 1780 1335 890 445
Deferred Taxes -303 -1552 -1214 -944 -651
Non-Cash Items 965 5718 5091 4152 3116
Changes in Working Capital -544 -1763 -1880 -1763 -1162
Cash From Investing Activities -826 -2466 -2091 -1378 -1070
Capital Expenditures -109 -728 -547 -390 -247
Other Investing Cash Flow Items, Total -717 -1738 -1544 -988 -823
Cash From Financing Activities -1406 -6469 -4915 -2797 -1794
Financing Cash Flow Items -134 -173 -150 -105 -91
Total Cash Dividends Paid -969 -3709 -2794 -1865 -945
Issuance (Retirement) of Stock, Net -303 -1087 -471 -327 -258
Issuance (Retirement) of Debt, Net 0 -1500 -1500 -500 -500
Foreign Exchange Effects 13 -63 -138 -66 -18
Net Change in Cash -476 74 -639 -599 -1042

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Gilead Company profile

What is Gilead Sciences?

Gilead Sciences Inc. is a US biopharmaceutical company. Following a series of mergers and acquisitions, Gilead is now one of the biggest players in its field with almost 9,000 employees working all over the globe. A portfolio of shipped products includes medicals for HIV treatment and HIV prevention. Gilead focuses on medical products that serve to cure oncology, liver diseases, cardiovascular disorders and many other severe health conditions. Gilead has a wide network of partnerships and collaborations.
 

What does the company do?

A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.

The portfolio of Gilead’s products and investigational drugs includes innovative treatments for AIDS/HIV, cancer, respiratory, inflammatory, liver diseases and cardiovascular conditions.
 

A bit of Gilead Sciences’ history

Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.

 

Who founded Gilead Sciences?

Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.

 

Establishing the company and its vision, Michael L. Riordan collaborated with three major scientific advisors, including Doug Melton of Harvard, Peter Dervan of Caltech and Harold Weintraub of the Fred Hutchinson Cancer Research Center.
 
A venture capital firm Menlo Ventures, where Riordan worked for one year, made the first investment of $2 million into Gilead Sciences.
 

Current size, team and locations

Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.

 

Quick facts about Gilead Sciences

  • Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
  • It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
  • In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
  • In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.

How to learn the Gilead Sciences share price?

Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the NASDAQ-100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.

Industry: Pharmaceuticals (NEC)

333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

Gold

2,392.09 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

BTC/USD

65,063.65 Price
+1.560% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.53 Price
+4.300% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

17,037.80 Price
-1.980% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading